Expert Analysis

Updates in HBV Management

Source: CCO Independent Conference Coverage of the 2006 Annual Meeting of the European Association for the Study of the Liver*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Updates in HBV Management


Faculty:

Yves Benhamou, MD, PhDGeoffrey M. Dusheiko, MD, FCP(SA), FRCPDaniel Shouval, MD
  • Yves Benhamou, MD, PhD
  • Geoffrey M. Dusheiko, MD, FCP(SA), FRCP
  • Daniel Shouval, MD

CME CREDIT INFORMATION

Release Date: 06/28/06

Expiration Date: 06/27/07


Physicians: maximum of 1.5 AMA PRA Category 1 Credits™

Status: Please log in to view status

Begin the Expert Analysis

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Review the results of recent studies evaluating the use of US Food and Drug Administration–approved agents in the treatment of hepatitis B virus (HBV) infection, including results related to drug resistance, predictors of response, and utility in special populations such as patients awaiting transplant
  • Discuss the results of trials of drugs in development for the treatment of HBV infection
  • Describe new data regarding predictors of hepatocellular carcinoma and risks of acquiring HBV through donor cells, tissues, and organs

Topics covered include:

  • Prevention of HBV Recurrence Following Transplantation
  • Transplantation With Anti-HBc–Positive Organs
  • Vaccination for Hepatitis B
  • Pharmacokinetics and Efficacy of Pradefovir
  • Phase III Telbivudine Studies
  • ANA 380 (LB80380) Efficacy Analysis
  • Off-Treatment Durability With Clevudine
  • New Data on Entecavir Therapy
  • New Data on Adefovir Therapy
  • New Data on Peginterferon Therapy
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grants provided by:

Educational grants support only the CME-certified components of this program.

CCO Resources

CCO Expert Recap of data from the 2006 Annual Meeting of the European Association for the Study of the Liver

CCO Expert Recap
CCO Slideset